RECRUITING

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)

Official Title

A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

Quick Facts

Study Start:2025-05-19

Study Completion:2027-04-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06868628

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Years to 85 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Subjects with a clinical diagnosis of Clinically Established or Clinically Probable Multiple System Atrophy in accordance with 2022 MDS diagnostic criteria. * Age 30 to 85 years, at the time of signing the informed consent. * Stable dopaminergic treatment for at least 4 weeks before enrollment. * Adequate hematologic parameters without ongoing transfusion support: Hemoglobin (Hb) ≥ 9 g/dL; Platelets ≥ 100 x 109 cells/L. * Creatinine ≤ 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance ≥ 60 mL/minute x 1.73 m2 per the Cockcroft-Gault formula. * Total bilirubin ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's disease. * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN. * QT interval corrected for rate (QTcF) ≤ 470 msec for women and ≤ 450 msec for men on the ECG obtained at Screening. * Negative urine pregnancy test within 7 days prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months). Sexually active WCBP and male patients must agree to use highly effective methods to avoid pregnancy (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study and for 90 days after the completion of study treatment. * Patients whose immunizations are fully up to date at the Screening, according to the assessment of their primary care physician and neurologist. * Ability to provide written informed consent.	* Diagnosis or suspicion of other cause for Parkinsonism or a known alternate neurologic diagnosis. * Female patient who is pregnant, lactating, breastfeeding, or planning to become pregnant during study. * Individuals with claustrophobia who cannot tolerate the study procedures * Non-MRI-compatible implanted devices. * Low-affinity binders for translocator protein (TSPO) PET ligands. * Systemic corticosteroid treatment in the past four weeks (excluding nasal or local treatment). * Individuals with significant cognitive impairment (i.e., MoCA score less than or equal to 20). * Brain MRI indicative of significant abnormalities that interfere with PET-MRI co-registration (i.e., large prior hemorrhage or multiple infarcts). * Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina, or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV or hereditary long QT syndrome. * Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, except for antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for patient care. * Patients who test positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) or positive Epstein-Barr virus (EBV) IgM at the Screening Visit. * Past medical history of a hematologic or solid malignancy. * Treatment with chronic immunosuppressives such as interferon, glatiramer acetate, fingolimod, Siponimod, dimethyl fumarate, or natalizumab within the past 90 days. * Inability to tolerate nasally administered medications. * Nasal corticosteroids, nasal antihistamines, nasal flu dosing within the past 30 days, or anticipated need during the study. * Chronic rhinitis, deviated septum, nasal polyps, history of sinusitis treated within the past 8 months. * Inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren's Syndrome, asthma, or type 1 diabetes. * Neutropenia or an absolute neutrophil count of \< 1,000 cells/mL or other indicators of severe immunosuppression. * Severe lymphopenia or an absolute lymphocyte count of \< 500 cells/mL * Patients with a history of gadolinium allergy. * A recent clinically significant active infection requiring treatment with antibiotics or other anti-infective agents within the past 15 days. * Any other medical or surgical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results. * Unable or unwilling to comply with protocol requirements. * Active COVID-19 disease. * COVID-19 vaccine within past 10 days or any other vaccine within past 7 days (at dosing).

Inclusion Criteria

Exclusion Criteria

* Subjects with a clinical diagnosis of Clinically Established or Clinically Probable Multiple System Atrophy in accordance with 2022 MDS diagnostic criteria.
* Age 30 to 85 years, at the time of signing the informed consent.
* Stable dopaminergic treatment for at least 4 weeks before enrollment.
* Adequate hematologic parameters without ongoing transfusion support: Hemoglobin (Hb) ≥ 9 g/dL; Platelets ≥ 100 x 109 cells/L.
* Creatinine ≤ 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance ≥ 60 mL/minute x 1.73 m2 per the Cockcroft-Gault formula.
* Total bilirubin ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's disease.
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN.
* QT interval corrected for rate (QTcF) ≤ 470 msec for women and ≤ 450 msec for men on the ECG obtained at Screening.
* Negative urine pregnancy test within 7 days prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months). Sexually active WCBP and male patients must agree to use highly effective methods to avoid pregnancy (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study and for 90 days after the completion of study treatment.
* Patients whose immunizations are fully up to date at the Screening, according to the assessment of their primary care physician and neurologist.
* Ability to provide written informed consent.

* Diagnosis or suspicion of other cause for Parkinsonism or a known alternate neurologic diagnosis.
* Female patient who is pregnant, lactating, breastfeeding, or planning to become pregnant during study.
* Individuals with claustrophobia who cannot tolerate the study procedures
* Non-MRI-compatible implanted devices.
* Low-affinity binders for translocator protein (TSPO) PET ligands.
* Systemic corticosteroid treatment in the past four weeks (excluding nasal or local treatment).
* Individuals with significant cognitive impairment (i.e., MoCA score less than or equal to 20).
* Brain MRI indicative of significant abnormalities that interfere with PET-MRI co-registration (i.e., large prior hemorrhage or multiple infarcts).
* Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina, or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV or hereditary long QT syndrome.
* Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, except for antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for patient care.
* Patients who test positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) or positive Epstein-Barr virus (EBV) IgM at the Screening Visit.
* Past medical history of a hematologic or solid malignancy.
* Treatment with chronic immunosuppressives such as interferon, glatiramer acetate, fingolimod, Siponimod, dimethyl fumarate, or natalizumab within the past 90 days.
* Inability to tolerate nasally administered medications.
* Nasal corticosteroids, nasal antihistamines, nasal flu dosing within the past 30 days, or anticipated need during the study.
* Chronic rhinitis, deviated septum, nasal polyps, history of sinusitis treated within the past 8 months.
* Inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren's Syndrome, asthma, or type 1 diabetes.
* Neutropenia or an absolute neutrophil count of \< 1,000 cells/mL or other indicators of severe immunosuppression.
* Severe lymphopenia or an absolute lymphocyte count of \< 500 cells/mL
* Patients with a history of gadolinium allergy.
* A recent clinically significant active infection requiring treatment with antibiotics or other anti-infective agents within the past 15 days.
* Any other medical or surgical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results.
* Unable or unwilling to comply with protocol requirements.
* Active COVID-19 disease.
* COVID-19 vaccine within past 10 days or any other vaccine within past 7 days (at dosing).

Contacts and Locations

Study Contact

Brigham and Women's Hospital Movement Research Team

CONTACT

507-491-0272

BWHMovementResearch@bwh.harvard.edu

Study Locations (Sites)

Brigham and Women's Hospital

Boston, Massachusetts, 02115

United States

Collaborators and Investigators

Sponsor: Tiziana Life Sciences LTD

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-19

Study Completion Date2027-04-01

Study Record Updates

Study Start Date2025-05-19

Study Completion Date2027-04-01

Terms related to this study

Additional Relevant MeSH Terms

Multiple System Atrophy